Mirzaten (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite disturbances associated with depression.

GNH USA supplies Mirzaten as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, ensuring quality manufacturing standards and reliable global logistics for regulated medicines. Our network supports timely delivery and regulatory documentation for importers and healthcare providers.

Mirtazapine, marketed as Mirzaten, is used within the antidepressant therapeutic class to address depressive disorders, particularly when patients present with sleep disturbances or appetite loss.

- Major depressive disorder: reduces depressive symptoms, improves mood, and enhances functional capacity in adult patients. - Depressive episodes associated with major depressive disorder: alleviates low mood, loss of interest, and associated cognitive deficits. - Depression with concomitant insomnia: may improve sleep quality while treating core depressive symptoms. - Adjunctive treatment of depression in patients with comorbid anxiety: may provide additional symptom relief.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation: drowsiness or feeling unusually sleepy, especially at treatment initiation. - Increased appetite/weight gain: heightened hunger leading to gradual weight increase. - Dry mouth: reduced salivation causing discomfort. - Constipation: slower bowel movements. - Dizziness: light‑headed sensation, particularly when standing quickly.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, requiring immediate medical attention. - Severe neutropenia: markedly low neutrophil count, increasing infection risk. - Suicidal thoughts: emergence of suicidal ideation, especially during early therapy. - Hepatotoxicity: rare liver injury presenting with jaundice or abnormal liver tests.

Before initiating therapy, clinicians should consider several safety measures.

- Weight monitoring: regularly assess body weight and appetite changes. - Suicidal ideation: monitor patients closely during the initial treatment phase. - Hepatic function: use caution in patients with liver impairment and adjust dose if needed. - Concomitant CNS depressants: avoid excessive sedation when combined with alcohol or benzodiazepines. - Discontinuation: taper gradually under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine can interact with various medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate hypertensive crisis or serotonin syndrome. - Other serotonergic antidepressants (SSRIs, SNRIs): increased risk of serotonin syndrome. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Antihypertensives: additive hypotensive effect, monitor blood pressure. - NSAIDs: heightened risk of gastrointestinal bleeding. - Lithium: monitor serum lithium levels for possible toxicity. - Warfarin: may enhance anticoagulant effect, check INR regularly.